SynthesisBone & joint research2026
Diagnostic biomarkers for non-traumatic osteonecrosis of the femoral head : a systematic review and pathophysiological cascade network.
Synthesis in Bone & joint research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Aims: Many studies have focused on identifying specific biomarkers for the early diagnosis of non-traumatic osteonecrosis of the femoral head (NONFH). This systematic review aims to summarize biomarkers associated with the diagnosis and progression prediction of NONFH, thereby providing a molecular level foundation for clinical diagnosis and targeted treatment. Methods: Following the PRISMA guidelines for systematic reviews, we comprehensively searched original English-language articles published between January 2015 and December 2025 in the Web of Science and PubMed databases. Studies were selected based on the PICOS framework. Extracted data included study design, methodologies, sample sources, identified biomarkers, predictive performance, and the potential pathological pathways involved. Results: Overall, 15 studies were included, reporting a total of 52 biomarkers, all derived from blood samples. Biomarkers from eight studies were used to reflect NONFH progression, while those from seven studies were using for diagnostic prediction purposes. All biomarkers demonstrated favourable predictive performance, with six studies providing external validation. The predictive model comprising ICAM1, NR3C1, IKBKB, and CD4 showed promising performance, with area under the receiver operating characteristic curve (AUC) values each reaching 1.00. Based on their core functions, the biomarkers were categorized into seven functional groups: immune-inflammatory activation and response, signal transduction and regulation, molecular metabolism and energy homeostasis, vascular function and coagulation, oxidative stress, pyroptosis and autophagy, and RNA regulatory. Conclusion: Biomarkers for NONFH exhibit considerable potential for early diagnosis and disease progression prediction in the Chinese population. The pathogenesis of NONFH involves a multifaceted pathological process in which various components interact and synergistically exacerbate the condition. This indicates that future therapeutic strategies should adopt a multitarget, multipathway synergistic intervention approach.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.